Get the Stockscreener App
3.82
73.97%
1.63
After Hours:
3.79
-0.03
-0.79%
Q 32 Bio Inc stock is traded at $3.82, with a volume of 166.79M.
It is up +73.97% in the last 24 hours and up +35.59% over the past month.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.
See More
Previous Close:
$2.19
Open:
$4.25
24h Volume:
166.79M
Relative Volume:
60.98
Market Cap:
$47.00M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+86.76%
1M Performance:
+35.59%
6M Performance:
+120.23%
1Y Performance:
-85.84%
1-Day Range:
$3.75
$6.3699
1-Week Range:
$1.98
$6.3699
52-Week Range:
$1.345
$28.06
Q 32 Bio Inc Stock (QTTB) Company Profile
Name
Q 32 Bio Inc
Sector
Industry
Phone
781-999-0232
Address
830 WINTER STREET, WALTHAM
Compare QTTB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
3.82 | 26.95M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.60 | 110.02B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.11 | 82.00B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.56 | 59.61B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
894.90 | 56.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
211.41 | 44.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-11-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-11-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | Raymond James | Strong Buy |
| Sep-11-24 | Initiated | Wells Fargo | Overweight |
| Jun-17-24 | Initiated | Guggenheim | Buy |
| May-21-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-22-22 | Reiterated | BTIG Research | Neutral |
| Feb-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-22-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-02-21 | Initiated | Stifel | Hold |
| Dec-14-20 | Resumed | H.C. Wainwright | Buy |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-16-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-24-20 | Initiated | Chardan Capital Markets | Buy |
| Nov-01-19 | Initiated | Oppenheimer | Perform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
View All
Q 32 Bio Inc Stock (QTTB) Latest News
Q32 Bio Inc. (QTTB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Q32 Bio (QTTB) Stock Explodes After $592 Million Akebia Deal – Latest News, Analyst Targets and 2027 Outlook - ts2.tech
Q32 Bio Stock Soars On Selling Experimental Drug To Akeba For Up To $592M - Stocktwits
Q32 Bio Inc. (QTTB) Stock: Jumps on Akebia Acquisition of ADX-097 and Extended Runway - parameter.io
Synopsys, Moderna, Strategy, Q32 Bio, Wolfspeed: Stocks Making The Biggest Moves Today - Stocktwits
Q32 Bio Shares Soar After Offloading Phase 2 Complement Drug to Akebia - MSN
QTTB Stock Surges: Market Insight - StocksToTrade
Dow Dips 200 Points; Q32 Bio Shares Jump - inkl
Why Is Small-Cap Q32 Bio Stock Soaring On Monday? - inkl
Akebia Therapeutics Sets Rare Kidney Drug Plan After Q32 Bio Deal - MarketScreener
Q32 Bio stock rockets after selling Phase 2 complement inhibitor to Akebia - Investing.com Nigeria
Q32 Bio Sells Complement Inhibitor ADX-097 - citybiz
Q32 Bio sells complement inhibitor Adx-097 - MarketScreener
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront - TipRanks
Akebia Therapeutics (AKBA) Acquires Phase 2 Drug from Q32 Bio - GuruFocus
Q32 Bio Sells ADX-097 to Akebia Therapeutics - TipRanks
Akebia Announces Establishment of Rare Kidney Disease Pipeline - The Manila Times
Cash per share of Q32 Bio Inc – LSE:0T6G - TradingView
Q32 Bio Inc.Common Stock (Nasdaq:QTTB) Stock Quote - Markets Financial Content
Form 8-KCurrent report - ADVFN
Layoff Tracker: Novartis Cuts 550 Employees as Swiss Manufacturing Priorities Shift - BioSpace
What analysts say about Q32 Bio Inc stockEarnings Volatility Patterns & High Return Trading Plans - earlytimes.in
Q32 Bio Inc Stock Analysis and ForecastInstitutional Buying Trends & Small Entry Cost Portfolio - earlytimes.in
Is Q32 Bio Inc. stock supported by strong fundamentalsJuly 2025 Volume & Growth Focused Stock Reports - newser.com
How strong is Q32 Bio Inc. stock balance sheetMarket Sentiment Review & Growth Focused Investment Plans - newser.com
Tick level data insight on Q32 Bio Inc. volatilityJuly 2025 Recap & Fast Entry Momentum Alerts - newser.com
Is Q32 Bio Inc. stock reversal real or fakeInsider Buying & Expert Verified Stock Movement Alerts - newser.com
Is Q32 Bio Inc. stock attractive for income investorsTrade Volume Report & Daily Technical Stock Forecast Reports - newser.com
How Perimeter Solutions SA stock reacts to weak economyJuly 2025 Volume & Daily Growth Stock Tips - Newser
Q32 Bio Inc. stock trendline breakdown2025 Top Gainers & Fast Gain Stock Tips - newser.com
Intraday pattern recognizer results for Q32 Bio Inc.Market Movement Recap & High Accuracy Swing Entry Alerts - newser.com
EBITDA per share of Q32 Bio Inc – SWB:DB0 - TradingView
Q32 Bio (QTTB) Receives a Buy from Oppenheimer - The Globe and Mail
Q32 Bio (QTTB) Price Target Increased by 13.33% to 11.56 - Nasdaq
Trend analysis for Q32 Bio Inc. this weekTrade Analysis Report & Community Consensus Trade Signals - newser.com
How Q32 Bio Inc. stock reacts to oil pricesLong Setup & Accurate Entry/Exit Alerts - newser.com
Q32 Bio Inc. (QTTB) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Why Q32 Bio Inc. stock is a must watch in 2025Weekly Trade Report & Community Verified Trade Alerts - newser.com
Sentiment analysis tools applied to Q32 Bio Inc.Weekly Gains Summary & High Conviction Trade Alerts - newser.com
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q - GlobeNewswire
Q32 Bio: Q3 Earnings Snapshot - Stamford Advocate
Price momentum metrics for Q32 Bio Inc. explained2025 EndofYear Setup & Growth Focused Stock Pick Reports - newser.com
Q32 Bio Inc. Faces Financial Challenges Amid Development Efforts - TipRanks
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update - The AI Journal
Q 32 Bio Inc Stock (QTTB) Financials Data
There is no financial data for Q 32 Bio Inc (QTTB). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Q 32 Bio Inc Stock (QTTB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Violette Shelia M. | Chief Scientific Officer |
Aug 26 '25 |
Sale |
1.80 |
2,990 |
5,385 |
58,384 |
| Kalowski Lee | CFO and President |
Aug 26 '25 |
Sale |
1.80 |
4,240 |
7,636 |
49,010 |
0.27%
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):